Key result
Aortoiliac atherosclerotic stenosis was associated with significantly lower patient survival compared to no stenosis (30.6% for TASC A/B and 11.4% for TASC C/D vs 44.1%).
Why the study?
The impact of aortoiliac occlusive disease on kidney transplantation remains unclear.
Does aortoiliac atherosclerotic stenosis impact patient survival and graft survival in patients undergoing kidney transplantation?
Cohort (n=655)
No
Does aortoiliac atherosclerotic stenosis impact patient survival and graft survival in patients undergoing kidney transplantation?
Aortoiliac atherosclerotic stenosis significantly reduces patient survival but not graft survival in kidney transplant recipients, with severe (TASC C/D) stenosis offering no survival benefit from transplantation.
BACKGROUND: The impact of aortoiliac occlusive disease on kidney transplantation remains unclear. This study aims to investigate the clinical outcomes of kidney transplant patients with aortoiliac atherosclerotic stenosis. METHODS: Retrospective data from our transplant center were used to identify patients undergoing kidney transplantation between January 2010 and December 2020. Aortoiliac atherosclerotic stenosis was screened and stratified by the Trans-Atlantic Inter-Society Consensus (TASC) II classification. The primary outcome was patient survival. Secondary outcomes were 90-day mortality, death-censored graft survival, graft function, and arterial complications. Propensity score matching was used to match all patients in the stenosis group with patients without stenosis sharing similar characteristics. RESULTS: The analysis included 655 patients, 524 without stenosis and 131 with aortoiliac stenosis (95 with TASC A/B stenosis and 36 with TASC C/D stenosis). Recipient age [median (IQR), 66 (60-70) vs. 66 (59-71) years; P =0.47], sex [male: 87 (66%) vs. 355 (68%), P =0.85], and comorbidities were comparable between the stenosis and no-stenosis groups. Forty-six (35%) patients with stenosis were symptomatic. Patient survival was significantly lower in the stenosis group compared with the no-stenosis group (TASC A/B: 30.6% vs. no-stenosis: 44.1%, P =0.013; TASC C/D: 11.4% vs. no-stenosis: 44.1%, P <0.001). The incidence rates of artery dissection, lower extremity ischemia, and acute thrombosis were significantly higher in the stenosis group ( P <0.001). However, death-censored graft survival (TASC A/B: 73.6% vs. no-stenosis: 72.9%, P =0.62; TASC C/D: 58.1% vs. no-stenosis: 72.9%, P =0.16) and graft function were comparable between the groups. CONCLUSIONS: Aortoiliac atherosclerotic stenosis significantly impacts patient survival but not graft survival. Our analyses suggest that patients with TASC A/B stenosis have prolonged survival and enhanced quality of life through kidney transplantation. However, for patients with TASC C/D stenosis, kidney transplantation improves quality of life without bringing survival benefits.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2023) conducted a cohort in Aortoiliac atherosclerotic stenosis in kidney transplantation (n=655). Aortoiliac atherosclerotic stenosis vs. No aortoiliac stenosis was evaluated on patient survival (p=0.013 for TASC A/B; <0.001 for TASC C/D). Aortoiliac atherosclerotic stenosis was associated with significantly lower patient survival compared to no stenosis (30.6% for TASC A/B and 11.4% for TASC C/D vs 44.1%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: